Boehringer Ingelheim is a privately held, research-driven biopharmaceutical company headquartered in Ingelheim am Rhein, Germany. Founded in 1885, it operates globally across human pharmaceuticals and animal health, developing, manufacturing, and supplying prescription medicines, biologics, and veterinary vaccines and therapeutics.
The company’s R&D spans respiratory and fibrotic diseases, cardiovascular and metabolic conditions, immunology, oncology, and central nervous system and retinal disorders. In animal health, it serves both companion animals and livestock with prevention and treatment solutions.
Boehringer Ingelheim maintains significant development and manufacturing capabilities, including large-scale biopharmaceutical production and process development. Through its contract manufacturing services, it supports third parties with clinical and commercial supply of therapeutic proteins and antibodies. The company also operates a global network of research and production sites in Europe, the United States, and Asia, and consistently reinvests a substantial share of its revenue into R&D.
